 PHILADELPHIA, PA, Feb. 09, 2021 GLOBE NEWSWIRE -- Vallon Pharmaceuticals, Inc. the Company, a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a public offering price of 8.00 per share, for gross proceeds of 18.0 million, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 337,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments. 